Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Cogstate Ltd ( (AU:CGS) ).
Cogstate Ltd announced the cessation of certain securities, specifically performance rights, due to the lapse of conditional rights that were not satisfied. This development may impact the company’s capital structure and could have implications for stakeholders, as it reflects adjustments in the company’s securities management.
The most recent analyst rating on (AU:CGS) stock is a Buy with a A$1.45 price target. To see the full list of analyst forecasts on Cogstate Ltd stock, see the AU:CGS Stock Forecast page.
More about Cogstate Ltd
Cogstate Ltd operates in the healthcare industry, specializing in the development and commercialization of cognitive tests and assessments. The company focuses on providing solutions for clinical trials, academic research, and healthcare, aiming to enhance the measurement of cognition in various settings.
YTD Price Performance: 33.49%
Average Trading Volume: 114,946
Technical Sentiment Signal: Buy
Current Market Cap: A$235.4M
For an in-depth examination of CGS stock, go to TipRanks’ Overview page.
Trending Articles:
- “…Overlook a Lack of Earnings Power”: UBS Analysts Target Intel Stock (NASDAQ:INTC), Stock Gains
- “…Significantly Extend the Reach and Lethality of our Fleet”: Boeing Stock (NYSE:BA) Slips Despite Successful MQ-25A Test
- “Direct Result of Your Feedback….” Microsoft Stock (NASDAQ:MSFT) Slips as The Option to Skip Updates Emerges